Astra seeks U.S. okay for Seroquel XR in anxiety
LONDON, May 8 (Reuters) - AstraZeneca Plc (AZN.L: Quote, Profile, Research) said on Thursday it had applied to U.S. regulators to sell its schizophrenia drug Seroquel XR as a treatment for anxiety.
If approved, Seroquel XR would be the first atypical antipsychotic medicine cleared for the treatment of generalised anxiety disorder.
Seroquel XR -- a follow-on extended release version of AstraZeneca's older $4 billion-a-year seller Seroquel -- was approved in the United States for schizophrenia in 2007. AstraZeneca is also seeking clearance to sell the new drug for bipolar disorder. (Reporting by Ben Hirschler)
© Thomson Reuters 2009 All rights reserved
UK joins G20 push for world levy on banks
Britain threw its weight behind proposals to impose a global levy on banks to fund future bailouts and called on the G20 to work toward a $100 billion deal to meet the cost of climate change. Full Article | Full Coverage
Galleon case
U.S. insider trading probe widens
Fourteen people were charged with fraud and conspiracy in a dramatic widening of an insider trading scandal. Full Article
India
US
UK
